Choosing CCR5 or Rev siRNA in HIV-1.
Arteaga
H Jose
HJ
Hinkula
Jorma
J
van Dijk-Härd
Iris
I
Dilber
M Sirac
MS
Wahren
Britta
B
Christensson
Birger
B
Mohamed
Abdalla J
AJ
Smith
C I Edvard
CI
D002460:Cell Line; D015694:Gene Products, rev / Q000378:metabolism*; D054303:HIV Reverse Transcriptase / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology / Q000235:genetics / Q000254:growth & development*; D009000:Monocytes / Q000821:virology; D012330:RNA, Double-Stranded / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D034741:RNA, Small Interfering / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology; D022661:RNA, Untranslated / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism; D019713:Receptors, CCR5 / Q000187:drug effects* / Q000378:metabolism; D014162:Transfection; D014779:Virus Replication / Q000187:drug effects*; D054321:rev Gene Products, Human Immunodeficiency Virus
D015694:Gene Products, rev; D012330:RNA, Double-Stranded; D034741:RNA, Small Interfering; D022661:RNA, Untranslated; D012367:RNA, Viral; D019713:Receptors, CCR5; D054321:rev Gene Products, Human Immunodeficiency Virus; D054303:HIV Reverse Transcriptase